Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 119-124

  Davies, T A ^a   Evangelista, A ^a   Pfleger, S ^a   Bush, K ^a   Sahm, D F ^a   Goldschmidt, R ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; LEVOFLOXACIN; PENICILLIN G; QUINOLONE; SERINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OLIGONUCLEOTIDE PROBE; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-INFECTIVE AGENTS; DNA TOPOISOMERASES, TYPE II; GENE FREQUENCY; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; POINT MUTATION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0036136859     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.119-124.2002     Document Type: Article

References (28)

1. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
2. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
3. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
4. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
5. Primary targets of fluoroquinolones in Streptococcus pneumoniae
6. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
7. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
8. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
9. The thermal stability of oligonucleotide duplexes is sequence independent in tetraalkylammonium salt solutions: Application to identifying recombinant DNA clones
10. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
11. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
12. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States
13. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program
14. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
15. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae
16. Fluoroquinolone resistance in Streptococcus pneumoniae
17. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit forming resistance phenotype
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
19. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting gyrase or topoisomerase IV by quinolones
20. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
21. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
22. Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program
23. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis
24. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae
25. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
26. Base composition-independent hybridization in tetramethylammonium chloride: A method for oligonucleotide screening of highly complex gene libraries